Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sabz Biomedicals
Tehran, Iransabzbiomedicals.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sabz Biomedicals has established protocols for the development and expansion of CD19-targeted CAR T cells. Their work demonstrates successful activation, expansion, and transduction of T cells with lentiviral vectors encoding anti-CD19 chimeric antigen receptors. This represents an important step toward enabling preclinical and future clinical studies for cancer immunotherapy in resource-limited settings.[5] There are no published clinical trial results yet.
- Therapeutic areas
- OtherOncology
- Modalities
- CAR-T cell therapyCell therapyLaboratory supplies (supporting research)Professional software (supporting research)
- Industry
- Biotech
Beyond the preview
Go deeper on Sabz Biomedicals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sabz Biomedicals.